Drug intelligence / Profile preview

diphtheria and tetanus toxoids

Development stage: Approved
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Diphtheria and tetanus toxoids are inactivated bacterial toxins used as active components in vaccines to induce immunity against diphtheria and tetanus. These toxoids stimulate the immune system to produce specific antibodies, thereby preventing the diseases caused by *Corynebacterium diphtheriae* and *Clostridium tetani*. They are frequently combined with acellular pertussis vaccine (forming DTaP or Tdap vaccines) or other vaccine components to provide broader protection.

Brand names: DT Vaccine Bio Farma
Other names: DT

Targets

Diphtheria toxin

Beyond the preview

Go deeper on diphtheria and tetanus toxoids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diphtheria and tetanus toxoids.

Explore the full profile